Bayesian Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-13,104
| Closed | -$527K | – | 236 |
|
|
2026
Q1 | $527K | Buy |
+13,104
| New | +$282K | 0.64% | 50 |
|
|
2025
Q4 | – | Sell |
-25,500
| Closed | -$577K | – | 138 |
|
|
2025
Q3 | $577K | Buy |
+25,500
| New | +$595K | 0.12% | 253 |
|
|
2025
Q2 | – | Sell |
-37,900
| Closed | -$829K | – | 537 |
|
|
2025
Q1 | $829K | Buy |
+37,900
| New | +$1.05M | 0.14% | 206 |
|
|
2024
Q4 | – | Sell |
-31,200
| Closed | -$900K | – | 678 |
|
|
2024
Q3 | $900K | Buy |
+31,200
| New | +$1.16M | 0.11% | 262 |
|
|
2024
Q1 | – | Sell |
-17,275
| Closed | -$1.03M | – | 770 |
|
|
2023
Q4 | $1.03M | Buy |
+17,275
| New | +$876K | 0.11% | 228 |
|
|
2023
Q3 | – | Sell |
-9,124
| Closed | -$831K | – | 685 |
|
|
2023
Q2 | $831K | Sell |
9,124
-8,800
| -49% | -$759K | 0.09% | 300 |
|
|
2023
Q1 | $1.18M | Buy |
+17,924
| New | +$1.03M | 0.15% | 209 |
|
|
2022
Q3 | – | Sell |
-11,600
| Closed | -$525K | – | 687 |
|
|
2022
Q2 | $525K | Sell |
11,600
-2,400
| -17% | -$109K | 0.1% | 322 |
|
|
2022
Q1 | $711K | Buy |
+14,000
| New | +$618K | 0.11% | 282 |
|
Other funds holding APLS
Bayesian Capital Management's APLS Position: Q2 2026 in Review
Bayesian Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 13,104 shares — an estimated $527K sold.
Bayesian Capital Management first reported a position in APLS in Q1 2022 and held it in 9 quarters. The position peaked at $1.18M in Q1 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Bayesian Capital Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Bayesian Capital Management sold 13,104 Apellis Pharmaceuticals shares in Q2 2026, an estimated $527K.
- Bayesian Capital Management first reported a position in Apellis Pharmaceuticals in Q1 2022 and held it in 9 quarters.
- Bayesian Capital Management's Apellis Pharmaceuticals position peaked at $1.18M in Q1 2023.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Bayesian Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.